

Care pathways


38,604 people

were diagnosed with bowel cancer in England and Wales between 1 April 2022 and 31 March 2023.

Proportion of people who presented with stage 1 or stage 2 cancer




Number of patients who presented with colorectal cancer by route of diagnosis*




*Data were impacted by the COVID-19 pandemic

Proportion of people recorded as being seen by a clinical nurse specialist (CNS)




Proportion of people in England with mismatch repair (MMR) immunohistochemistry test




Data on MMR tests is only available for people diagnosed in England until 31 December 2021


Peri-operative care




% of people who died within 90 days of surgery



% of people with an unplanned 30-day return to theatre after surgery




% of people with an unclosed diverting ileostomy 18-months after anterior resection (major rectal cancer operation, year of surgery)



% of people with an unplanned 30-day readmission after surgery



% of trusts/MDTs that performed ≥ 20 major rectal cancer operations per year (year of surgery)



% of people who underwent major colorectal cancer surgery with a minimally invasive approach


Oncological management




% of people who received adjuvant chemotherapy for stage 3 colon cancer (year of surgery)



% of people who experienced severe acute toxicity after adjuvant chemotherapy (year of surgery)



% of people with rectal cancer who received neo-adjuvant radiotherapy treatment (year of diagnosis)



% of people alive 2-years after major colorectal cancer surgery (year of surgery)